NINLARO®

NINLARO®

Naming | Pharma

The Situation

Takeda Oncology – Cambridge, Massachusetts-based business unit of the multimillion-dollar, global Company – approached Brandsymbol to quickly deliver world-class backup proprietary solutions for two products in development:

1. ixazomib, a type of cancer drug referred to as a protease inhibitor; and

2. alisertib, a cancer drug that binds to, and inhibits the Aurora A kinase.

Takeda Oncology had previously undertaken name development projects for both products, however were not confident in the ability of the created names to clear the regulatory bodies. This ambiguity urged their product team to challenge Brandsymbol with delivering optimal and ownable options to add to the existing names and instill confidence when submitting to regulatory.

The Solution

Brandsymbol delivered appealing and viable Brand names that served well as backup options on time and on budget. The names afforded Takeda Oncology with strong options that prepared them for any eventuality from global regulatory submissions. Leading to ixazomib’s approval of the name NINLARO® with alisertib remaining in development.

The Success

Brandsymbol delivered appealing and viable brand names that served well as backup options on time and on budget. The names afforded Takeda Oncology with strong options that prepared them for any eventuality from global regulatory submissions. Leading to ixazomib’s approval of the name NINLARO® with alisertib remaining in development.